Christina Vorvis, PhD

• Opportunity Sourcing and Evaluation: Actively seek out promising early-stage companies and technologies that align with AbbVie's strategic focus areas (e.g., oncology, immunology, neuroscience). This involves networking with venture capitalists, attending industry events, and staying updated on emerging trends. Conduct thorough due diligence on potential investments, assessing scientific validity, market potential, and financial viability.
• Deal Execution and Negotiation: Lead the investment process, including structuring deals, negotiating terms, and managing the due diligence process. Collaborate with internal stakeholders (e.g., legal, finance, R&D) to ensure alignment and facilitate the closing of investments.
• Portfolio Management and Value Creation: Actively monitor and support AbbVie Ventures' portfolio companies. Provide strategic guidance, leverage AbbVie's resources and expertise to help companies grow and achieve milestones. Identify opportunities for collaboration and potential partnerships between portfolio companies and AbbVie.
• Internal Stakeholder Engagement: Build and maintain relationships with key stakeholders across AbbVie (e.g., research, business development, commercial). Effectively communicate investment rationale, progress, and potential impact to internal audiences. Advocate for portfolio companies within AbbVie to ensure support and alignment.
• Industry and Ecosystem Engagement: Represent AbbVie Ventures at industry events, conferences, and partner meetings. Build relationships with venture capital firms, incubators, and other key players in the biotech ecosystem. Contribute to AbbVie's reputation as a committed and active participant in the venture capital community.
• Active Member, Board of Directors:

1. Kojin Therapeutics (Boston, MA)

2. Accent Therapeutics (Lexington, MA)

3. XenImmune Therapeutics (Boston, MA)

• Point-of-contact in communicating/meeting with clients and counterparties to transaction (and professional advisors)
• Review and prepare transaction-related documentation and marketing materials including confidential information memoranda, pitch books, teasers, and management presentations
• Leverage understanding of sector trends and strategic direction of clients to win new business
• Successfully leveraged professional network to source M&A targets for public, NASDAQ-listed specialty pharmaceutical buy-side M&A client, leading to our client submitting $350M in non-binding term sheets or letters of intent to prospective counterparty
• Completed fairness opinion and prepared transaction analysis deck for the Board of Managers of Novellus Therapeutics in acquisition by Brooklyn ImmunoTherapeutics (NASDAQ: BTX) announced in July, 2021
• Completed fairness opinion and transaction analysis deck for Board of Directors of Caladrius Biosciences (NASDAQ: CLBS) in merger of equals transaction with Cend Therapeutics announced in April, 2022
• Support Managing Directors and Directors in all aspects of firm marketing, business development, and deal execution
• Maintain existing relationships with clients and build a strong network, as well as build relationships and maintain direct contact with clients, prospective clients, and professional advisors
• Coordinate and perform business due diligence and execute M&A transactions
• Significant role in recruiting, training, and mentoring junior professionals

• Joined the pre-series A company when it had four employees and immediately hired an additional three FTEs with backgrounds in healthcare technology across key functions (i.e., VP of Product, Manager of Client Services, etc.)
• Negotiated and drafted contracts and pilots with business partners, clients, and vendors such as Walmart, Sam's Club, McKesson, New York Presbyterian Hospital, adding ~$350,000 in multi-year contracts
• Developed and commercialized a module for ordering, tracking, and billing durable medical equipment for independent practice associations (IPAs)
• Developed and commercialized a module for ordering, tracking, and billing durable medical equipment used at the point-of-care for discharge nurses and medical staff in a hospital setting
• Maintained 100% client retention while negotiating and executing statement of work and master service agreements with clients
• Shaped solutions and approaches by leveraging trends in customer marketplaces and industries
• Drafted licensing agreements for our clients

• Led deal origination & scientific due diligence, covering private and public companies operating in the biotechnology, pharmaceutical, diagnostic, medical device, and healthcare IT sectors
• Sourced and closed on Health Catalyst's (NASDAQ: HCAT) $100M Series F debt and equity funding round (led by OrbiMed) ~six months before the IPO
• Maintained a viable deal flow pipeline, whereby 20% of independently, organically-sourced investment opportunities converted into non-binding term sheets, equating to ~$2.5B
• Developed and implemented a process for proactively and efficiently sourcing and tracking new investment opportunities by building a custom CRM platform designed to track outreach efforts, manage the deal-flow process and capture key performance metrics
• Leveraged deep technical and scientific expertise to evaluate opportunities and enhance the quality and quantity of deal flow
• Prepared and presented investment memoranda to internal investment committee
• Acted as an ambassador to the firm by attending industry conferences and cultivated relationships with company executives and board members

• Deal closed: Preclinical License And Collaboration Agreement In Inflammation with Array Biopharma (NASDAQ: ARRY) for discovery and development of novel drugs for autoimmune disorders (undisclosed target)
• Pre-screened and accessed opportunities (>900 in nine months) for in/out-licensing, collaboration, M&A or venture investment across all R&D stages and therapeutic areas (Oncology, Inflammation, Metabolism, Cardiovascular, Neuroscience, Nephrology, and Bone)
• Scheduled and prepared agenda for monthly global cross-functional meetings including R&D, commercial, CMC, IP, regulatory and transactions
• Partnered with External R&D staff to enhance business processes and identify areas for process improvement and standardization
• Prepared slides for annual strategic reviews and proposals presented to CEO and executive team regarding the internal pipeline vs. competitive landscape, leading up to recommendations officially integrated into Amgen's 2017 inflammation strategic vision

• Focused on the identification and molecular characterization of pancreatic tumor-initiating cells
• Conducted high-throughput screenings and integrated transcriptomic analysis to characterize the molecular interactome of human pancreatic cancer

• Expressed and purified human heat-shock proteins (Hsp) from E. coli to understand the structural changes and coupling mechanisms that enable ATP-hydrolysis
• Identified and characterized two key amino acid residues in the Hsp70 protein that are functionally important in mediating interaction with other proteins